Neurogenic painful inflammation

Current Opinion in Anaesthesiology

Volumn 17, Issue 5, 2004, Pages 461-464

  Brack, Alexander ^a   Rittner, Heike L ^a   Stein, Christoph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Complex regional pain syndrome; Migraine; Neurogenic; Neuropeptide; Pain

Indexed keywords

NEUROPEPTIDE; PROTEINASE ACTIVATED RECEPTOR 2; VANILLOID RECEPTOR 1;

ANTINOCICEPTION; COMPLEX REGIONAL PAIN SYNDROME; ELECTROSTIMULATION; GENE EXPRESSION; HEADACHE; HORMONE RELEASE; HUMAN; IMMUNOCOMPETENT CELL; MIGRAINE; MOUSE; NERVE ENDING; NEUROGENIC INFLAMMATION; NONHUMAN; PAIN; PERIPHERAL NERVE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SENSORY NERVE; SENSORY NERVE CELL; SYSTEMATIC REVIEW;

EID: 4944234404     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200410000-00018     Document Type: Review

References (28)

1. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002; 302:839-845.
2. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288:306-313.
3. Neubert JK, Karai L, Jun JH, et al. Peripherally induced resiniferatoxin analgesia. Pain 2003; 104:219-228.
4. Karai L, Brown DC, Mannes AJ, et al. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J Clin Invest 2004; 113:1344-1352. This excellent paper evaluates a novel therapeutic strategy to treat pain; intrathecal injection of a TRPV-1 receptor agonist destroys C-fibers and reduces arthritic and neoplastic pain in dogs.
5. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; 328:991-1000.
6. Vergnolle N, Ferazzini M, D'Andrea MT, et al. Proteinase-activated receptors: novel signals for peripheral nerves. Trends Neurosci 2003; 26:496-500.
7. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6:151-158.
8. Hoogerwerf WA, Zou L, Shenoy M, et al. The proteinase-activated receptor 2 is involved in nociception. J Neurosci 2001; 21:9036-9042.
9. Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 2001; 7:821-826.
10. Dai Y, Moriyama T, Higashi T, et al. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. J Neurosci 2004; 24:4293-4299. This experimental study describes a novel interaction between PAR-2 receptors and TRPV1 channels. Activation of PAR-2 leads to phosphorylation of TRPV1. Thereby, TRPV1 can subsequently be activated by significantly lower temperatures (i.e. body temperature).
11. Amadesi S, Nie J, Vergnolle N, et al. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004; 24:4300-4312. This experimental study demonstrates that PAR-2 activation leads to phosphorylation of TRPV1 channels. Blockage or deletion of TRPV1 channels significantly reduces thermal hyperalgesia.
12. Ferrell WR, Lockhart JC, Kelso EB, et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 2003; 111:35-41.
13. Eisenberg E, Melamed E. Can complex regional pain syndrome be painless? Pain 2003; 106:263-267.
14. Jänig W, Baron R. Complex regional pain syndrome: mystery explained? Lancet Neurol 2003; 2:687-697. This outstanding and detailed review article describes the different aspects of the pathophysiology of CRPS. Furthermore, it summarizes the evidence that CRPS might be a systemic disease.
15. Baron R, Schattschneider J, Binder A, et al. Relation between sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional pain syndromes: a case-control study. Lancet 2002; 359:1655-1660.
16. Weber M, Birklein F, Neundorfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 2001; 91:251-257.
17. Leis S, Weber M, Isselmann A, et al. Substance-P-induced protein extravasation is bilaterally increased in complex regional pain syndrome. Exp Neurol 2003; 183:197-204.
18. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001; 57:2179-2184.
19. Quo TZ, Offley SC, Boyd EA, et al. Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004; 108:95-107. This study describes for the first time an animal model of CRPS. It supports previous clinical studies by showing that pain in CRPS is probably not directly related to the secretion of neuropeptides from peripheral nerve terminals and, thus, to neurogenic inflammation.
20. Dux M, Santha P, Jancso G. Capsaicin-sensitive neurogenic sensory vasodilatation in the dura mater of the rat. J Physiol 2003; 552 (Pt 3):859-867.
21. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002; 346:257-270.
22. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106:461-470. This experimental study shows that nitrous oxide induces migraine attacks in susceptible patients. Furthermore, it demonstrates a direct correlation between headache scores and CGRP plasma concentrations.
23. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-1110. This outstanding prospective randomized double-blind trial demonstrates that CGRP antagonists significantly improve headaches during migraine attacks. This might prove to be a landmark study since it suggests that inhibition of neurogenic inflammation is feasible and ameliorates pain.
24. Durham PL. CGRP-receptor antagonists: a fresh approach to migraine therapy? N Engl J Med 2004; 350:1073-1075. In this editorial, the potential mechanisms by which CGRP receptor antagonists improve headaches in patients with a migraine attack are discussed in detail. These include interference with neurogenic inflammation, inhibition of vasodilatation or blockage of C fiber activation.
25. Bong GW, Rosengren S, Firestein GS. Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation: the role of N-methyl-D-aspartate receptors. J Clin Invest 1996; 98:2779-2785.
26. Boyle DL, Moore J, Yang L, et al. Spinal adenosine receptor activation inhibits inflammation and joint destruction in rat adjuvant-induced arthritis. Arthritis Rheum 2002; 46:3076-3082.
27. Sorkin LS, Moore J, Boyle DL, et al. Regulation of peripheral inflammation by spinal adenosine: role of somatic afferent fibers. Exp Neurol 2003; 184:162-168.
28. Schmitt TK, Mousa SA, Brack A, et al. Modulation of peripheral endogenous opioid analgesia by central afferent blockade. Anesthesiology 2003; 98:195-202.